High Quality LRRK2 Antibodies for Parkinson's Disease Research
Novel LRRK2 Antibodies from Epitomics and MJFF
Well-characterized antibodies to efficiently detect and purify LRRK2 protein
are a critical need in the Parkinson's Disease (PD) research community. To help accelerate LRRK2 research,
The Michael J. Fox Foundation (MJFF), working with Epitomics, Inc., has generated several unique and high quality LRRK2 rabbit monoclonal
antibodies.
After primary characterization organized by MJFF and based on PD research community's feedback, three clones exhibiting the best performance were selected for distribution via Epitomics.
To see a complete list of LRRK2 and their characterization data, please click here.
To see the press release regarding Epitomics and MJFF's collaboration on LRRK2 RabMAbs click here
About LRRK2 and LRRK2 Antibodies
Discovered in 2004, LRRK2 (Leucine-rich repeat kinase 2, dardarin) is a protein kinase coded by human LRRK2 gene. LRRK2 gene mutation is the most common cause of inherited Parkinson's disease (1, 2).
While it is the focus of intensive research in the Parkinsons field, a major roadblock to the successful development of LRRK2-based therapies has been the lack of high-quality LRRK2 antibodies.
In 2009, MJFF convened a LRRK2 Antibodies Working Group composed of academic and industry researchers with specific expertise in LRRK2. At the recommendation of this group,
MJFF engaged Epitomics, Inc., to generate several highly sensitive and specific LRRK2 antibodies in large scale.
Epitomics LRRK2 Antibodies
| Cat# | Clone ID | Applications | Crossreactivity | Academic Price | For-Profit Price |
|---|---|---|---|---|---|
| 3514-1 | MJFF2 (c41-2) | WB, IHC, ICC, IP | Hu, Ms, Rt | $55 | $95 |
| 3515-1 | MJFF3 (c69-6) | WB, IHC, ICC, IP | Hu, Ms, Rt | $55 | $95 |
| 3516-1 | MJFF4 (c81-8) | WB, IHC, ICC, IP | Ms, Rt | $55 | $95 |
Characterization Data
Epitomics LRRK2 antibodies were generated against human LRRK2 fragment (amino acids 970-2527). These clones were characterized in multiple applications with the help of PD research community (3).
The data from the characterization study is shown below (Figure 1, 2). Click on the data to enlarge (opens a separate window).
Figure 1. Western Blotting using LRRK2 antibodies. Lane1: HEK293 cell lysate transfected with 3*Flag vector. Lane2: HEK293 cell lysate transfected with 3*Flag-wild type hLRRK2_full length. Data provided by Zhuohua Zhang Lab (Sanford-Burnham Medical Research Institute).
Figure 2. Immunohistochemistry analysis using anti-LRRK2 RabMAb (cat. #3514-1, MJFF-2 (c41-2)) on mouse and human brain FFPE tissue sections. Data provided by Zhuohua Zhang Lab (Sanford-Burnham Medical Research Institute).
About Michael J. Fox Foundation and Epitomics
The Michael J. Fox Foundation is dedicated to finding a cure for Parkinsons disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinsons today.
To learn more about MJFF, please visit www.michaeljfox.org.
Epitomics is an emerging biotechnology company, dedicated to developing their breakthrough monoclonal antibody technology (RabMAb) for research, diagnostics and therapeutics. The company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics.
To learn more about Epitomics and its patented RabMAb technology, please click here.
References
- 1. Deciphering the role of heterozygous mutations in genes associated with parkinsonism,
Kline C, et al., Lancet Neurol. 2007 Jul;6(7):652-62. - 2. The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other
neurodegenerative diseases, Hernandez D, et al., Neurosci Lett. 2005 Dec 9;389(3):137-9 - 3. PD Online Research
- 4. Antibodies for Parkinsons disease research available for validation
Andrew S. Wiecek., Biotechnique 2010 - 5. Description of Parkinson's disease as a clinical syndrome.
Fahn S; Ann N Y Acad Sci. 2003 Jun;991:1-14 - 6. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD.
Parkinson Study Group; Neurology. 2004 Jan 27;62(2):330-2
